Skip to main content
Fig. 4 | Applied Cancer Research

Fig. 4

From: Biomarker testing for advanced lung cancer by next-generation sequencing; a valid method to achieve a comprehensive glimpse at mutational landscape

Fig. 4

(a) Kaplan-Meier survival curve showing Progression-Free Survival (PFS) in patients with isolated single and compound EGFR mutations (n = 16). (b) Pathway specific co-mutations (encircled) as observed in the compound EGFR mutant group. (c) OncoPrint presenting the summary of the twenty-three EGFR mutated tumors for the single [1,2,3,4,5,6,7,8,9,10,11] and compound [12,13,14,15,16,17,18,19,20,21,22,23] mutation groups and the patients’ response to TKI therapy. The response could not evaluated in the cases 9, 10, 11, 20, 21, 22 and 23 as they were outpatients/ not treated by TKI. A: Afatinib, E: Erlotinib, G: Gefitinib, O: Osimertinib

Back to article page

Applied Cancer Research

ISSN: 1980-5578